Abstract
A new peptidic protease inhibitor (MpI) has been isolated from Maclura pomifera seeds, being the first trypsin and chymotrypsin inhibitor from a species belonging to the family Moraceae. MpI was purified by acetone precipitation, gel filtration and ion exchange chromatography, successively, with purification factors of 112 and 109 for the aforementioned enzymes, which are infrequent high values for inhibitors isolated from seeds. MpI showed a unique band in SDSTricine PAGE (Mr 11 kDa) and isoelectric focusing (pI = 5.2), inhibited the serine proteases trypsin and α-chymotrypsin (IC50 0.17 and 0.7 μg/ml, respectively), but not cathepsin B (cysteine protease), cathepsin D (aspartic protease) nor carboxypeptidase A (metallo protease). The N-terminal sequence was determined (AREPKFSTHCEEEESR) but no homology was detected with other peptide inhibitors isolated from seeds. Preliminary assays related to blood clotting reactions showed that the isolated inhibitor significatively increased the activated partial thromboplastin time (APTT), suggesting its potential use in the treatment of blood coagulation disorders.
Keywords: Maclura pomifera seeds, Peptide trypsin inhibitor, Peptide α-chymotrypsin inhibitor, Moraceae
Letters in Drug Design & Discovery
Title: A Novel Trypsin and α-Chymotrypsin Inhibitor from Maclura pomifera Seeds
Volume: 7 Issue: 4
Author(s): C. M. Lazza, S. A. Trejo, W. D. Obregon, L. G. Pistaccio, N. O. Caffini and L. M.I. Lopez
Affiliation:
Keywords: Maclura pomifera seeds, Peptide trypsin inhibitor, Peptide α-chymotrypsin inhibitor, Moraceae
Abstract: A new peptidic protease inhibitor (MpI) has been isolated from Maclura pomifera seeds, being the first trypsin and chymotrypsin inhibitor from a species belonging to the family Moraceae. MpI was purified by acetone precipitation, gel filtration and ion exchange chromatography, successively, with purification factors of 112 and 109 for the aforementioned enzymes, which are infrequent high values for inhibitors isolated from seeds. MpI showed a unique band in SDSTricine PAGE (Mr 11 kDa) and isoelectric focusing (pI = 5.2), inhibited the serine proteases trypsin and α-chymotrypsin (IC50 0.17 and 0.7 μg/ml, respectively), but not cathepsin B (cysteine protease), cathepsin D (aspartic protease) nor carboxypeptidase A (metallo protease). The N-terminal sequence was determined (AREPKFSTHCEEEESR) but no homology was detected with other peptide inhibitors isolated from seeds. Preliminary assays related to blood clotting reactions showed that the isolated inhibitor significatively increased the activated partial thromboplastin time (APTT), suggesting its potential use in the treatment of blood coagulation disorders.
Export Options
About this article
Cite this article as:
Lazza M. C., Trejo A. S., Obregon D. W., Pistaccio G. L., Caffini O. N. and Lopez M.I. L., A Novel Trypsin and α-Chymotrypsin Inhibitor from Maclura pomifera Seeds, Letters in Drug Design & Discovery 2010; 7 (4) . https://dx.doi.org/10.2174/157018010790945832
DOI https://dx.doi.org/10.2174/157018010790945832 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Ghrelin and Motilin in the Gastrointestinal System
Current Pharmaceutical Design Antiangiogenic Resistance and Cancer Metabolism: Opportunities for Synthetic Lethality
Current Drug Targets Concepts of Egr-1 Activation – A Hub for Signal Transduction Cascades
Current Signal Transduction Therapy The Protective Effects of Extra Virgin Olive Oil on Immune-mediated Inflammatory Responses
Endocrine, Metabolic & Immune Disorders - Drug Targets Novel Drug Delivery Systems for Sustained and Targeted Delivery of Anti-Cancer Drugs: Current Status and Future Prospects
Current Drug Delivery Breast Reconstruction – A Historical Perspective on Available Techniques for Patients Electing Bilateral Mastectomy
Current Cancer Therapy Reviews NSAIDs Induced Regulation of Alternatively Spliced Transcript Isoforms: Possible Role in Cancer and Alzheimer Disease
Current Cancer Drug Targets Recent Advances in Antabuse (Disulfiram): The Importance of its Metal-binding Ability to its Anticancer Activity
Current Medicinal Chemistry Natural and Synthetic Agents Targeting Inflammation and Angiogenesis for Chemoprevention of Prostate Cancer
Current Cancer Drug Targets Biosafety of Recombinant Adeno-associated Virus Vectors
Current Gene Therapy Applications of Nanomaterials for Cancer Treatment: Recent Patents Review
Recent Patents on Nanomedicine Heat Shock Proteins as Prognostic Markers of Cancer
Current Cancer Drug Targets Dietary Phenolic Acids and Flavonoids as Potential Anti-Cancer Agents: Current State of the Art and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry HER-2 Positive Breast Cancer: What Else Beyond Trastuzumab-Based Therapy?
Anti-Cancer Agents in Medicinal Chemistry Biologic Therapy in Immune Mediated Inflammatory Disease: Basic Science and Clinical Concepts
Current Drug Safety Targeting Hypoxia-Inducible Factor-1 (HIF-1) Signaling in Therapeutics: Implications for the Treatment of Inflammatory Bowel Disease
Recent Patents on Inflammation & Allergy Drug Discovery New Hopes in Cancer Battle - A Review of New Molecules and Treatment Strategies
Medicinal Chemistry The V-ATPase as a Target for Antifungal Drugs
Current Protein & Peptide Science Potential Uses of MicroRNA in Lung Cancer Diagnosis, Prognosis, and Therapy
Current Cancer Drug Targets Microalbuminuria: A Neglected Cardiovascular Risk Factor in Non-diabetic Individuals?
Current Pharmaceutical Design